Open-label, Randomized, Multi-Centre study to evaluate safety and efficacy of Remogliflozin in patients with Type 2 diabetes mellitus with acute decompensated heart failure (HF with reduced ejection fraction, HFrEF). (Remo Safe-AHF Study)
Title:
Open-label, Randomized, Multi-Centre study to evaluate safety and efficacy of Remogliflozin in patients with Type 2 diabetes mellitus with acute decompensated heart failure (HF with reduced ejection fraction, HFrEF). (Remo Safe-AHF Study)